News

These data suggest that GS 9350 has significant and selective pharmacoenhancing ability, no antiviral activity against HIV and differentiated biological properties in vitro compared to ritonavir, currently the

This includes $191 million of revenue from its recent acquisition of Applied Biosystems (AB), which closed on November 21, 2008. The closing date of the transaction resulted in

The improved delivery catheter enhances the previous version of the Gore Tag thoracic endoprosthesis by adding a soft flexible tip to the leading end of the delivery system.

The action is part of an overall cost-cutting program as the company works toward resuming full operation. The company has encountered a number of substantial challenges over the

The milestone payment arises from a drug discovery agreement between Schering-Plough and Pharmacopeia wherein Pharmacopeia contributed to Schering-Plough’s medicinal chemistry optimization of compounds discovered by Schering-Plough. Ligand completed

Fourth Quarter Results Net earnings were $118.1 million, against fourth quarter 2007 net earnings of $114.4 million. Excluding restructuring and other special items recorded in 2008 and 2007,

Mr Lehner reports to Marc Cluzel, senior vice president of R&D at Sanofi-Aventis. The chief medical officer will also chair the internal benefit/risk assessment committee created in 2008

The two-year project ‘drug discovery for bone and joint protection: structural biology for novel targets and their inhibitors’ focuses on Galapagos’s novel drug targets and the candidate drugs

Antisoma and Novartis have a worldwide development and commercialization agreement for ASA404. Trials in breast cancer will be in addition to two ongoing pivotal Phase III trials in